Ou SI - Search Results

1

From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK+ NSCLC.

Ou SI, Lee ATM, Nagasaka M. Ou SI, et al. Crit Rev Oncol Hematol. 2023 Jul;187:104019. doi: 10.1016/j.critrevonc.2023.104019. Epub 2023 May 13. Crit Rev Oncol Hematol. 2023. PMID: 37187318 Free article. Review.

2

Liquid Biopsy to Identify Actionable Genomic Alterations.

Ou SI, Nagasaka M, Zhu VW. Ou SI, et al. Am Soc Clin Oncol Educ Book. 2018 May 23;38:978-997. doi: 10.1200/EDBK_199765. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231331 Free PMC article. Review.

3

Neuregulin 1 Fusion-Positive NSCLC.

Nagasaka M, Ou SI. Nagasaka M, et al. Among authors: ou si. J Thorac Oncol. 2019 Aug;14(8):1354-1359. doi: 10.1016/j.jtho.2019.05.015. Epub 2019 May 22. J Thorac Oncol. 2019. PMID: 31128291 Free article. No abstract available.

4

Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.

Xia H, Xue X, Ding H, Ou Q, Wu X, Nagasaka M, Shao YW, Hu X, Ou SI. Xia H, et al. Among authors: ou si, ou q. Clin Lung Cancer. 2020 May;21(3):247-254. doi: 10.1016/j.cllc.2019.09.004. Epub 2019 Sep 26. Clin Lung Cancer. 2020. PMID: 31761448

5

KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?

Nagasaka M, Li Y, Sukari A, Ou SI, Al-Hallak MN, Azmi AS. Nagasaka M, et al. Among authors: ou si. Cancer Treat Rev. 2020 Mar;84:101974. doi: 10.1016/j.ctrv.2020.101974. Epub 2020 Jan 23. Cancer Treat Rev. 2020. PMID: 32014824 Free PMC article. Review.

6

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases.

Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI. Zhu VW, et al. Among authors: ou si. Lung Cancer (Auckl). 2020 Jan 14;11:13-18. doi: 10.2147/LCTT.S224991. eCollection 2020. Lung Cancer (Auckl). 2020. PMID: 32021525 Free PMC article.

7

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.

Yang G, Li J, Xu H, Yang Y, Yang L, Xu F, Xia B, Zhu VW, Nagasaka M, Yang Y, Li Y, Qiu W, Ying J, Ou SI, Wang Y. Yang G, et al. Among authors: ou si. Lung Cancer. 2020 Jul;145:186-194. doi: 10.1016/j.lungcan.2020.03.014. Epub 2020 Mar 18. Lung Cancer. 2020. PMID: 32336530

8

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.

Zhu VW, Lin YT, Kim DW, Loong HH, Nagasaka M, To H, Ang YL, Ock CY, Tchekmedyian N, Ou SI, Syn NL, Reungwetwattana T, Lin CC, Soo RA. Zhu VW, et al. Among authors: ou si. J Thorac Oncol. 2020 Sep;15(9):1484-1496. doi: 10.1016/j.jtho.2020.04.019. Epub 2020 Apr 28. J Thorac Oncol. 2020. PMID: 32360579 Free article.

9

A user's guide to lorlatinib.

Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SI. Nagasaka M, et al. Among authors: ou si. Crit Rev Oncol Hematol. 2020 Jul;151:102969. doi: 10.1016/j.critrevonc.2020.102969. Epub 2020 May 11. Crit Rev Oncol Hematol. 2020. PMID: 32416346 Free article. Review.

10

Is NRG2α Fusion a "Doppelgänger" to NRG1α/β Fusions in Oncology?

Nagasaka M, Ou SI. Nagasaka M, et al. Among authors: ou si. J Thorac Oncol. 2020 Jun;15(6):878-880. doi: 10.1016/j.jtho.2020.02.020. J Thorac Oncol. 2020. PMID: 32471560 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

190 results

Search Page